Related Experiment Video
Updated: Mar 14, 2026

09:19
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
9.8K
Uncovering distinct clinical phenotypes in disseminated intravascular coagulation through machine learning-enabled
Qingbo Zeng1,2, Junjie Zeng1, Qingwei Lin1
1Intensive Care Unit, The 908th Hospital of Chinese PLA Logistic Support Force, Nanchang, China.
Frontiers in Molecular Biosciences
|March 13, 2026
Summary
Machine learning identified two disseminated intravascular coagulation (DIC) subtypes in ICU patients: mild and severe. The severe subtype showed higher mortality risk, aiding personalized treatment for this critical condition.
Area of Science:
- Critical Care Medicine
- Computational Biology
- Hematology
Background:
- Disseminated intravascular coagulation (DIC) is a life-threatening ICU condition with varied causes and outcomes.
- Differentiating DIC patient phenotypes is challenging, hindering personalized treatment strategies.
Purpose of the Study:
- To apply unsupervised machine learning (ML) for stratifying DIC patients into distinct phenotypes.
- To enable more personalized treatment approaches for DIC based on identified subtypes.
Main Methods:
- Retrospective analysis of 134 DIC patients admitted to the ICU.
- Unsupervised machine learning (consensus clustering) using key variables: Thrombin-Antithrombin Complex (TAT), Plasmin-α2-Plasmin Inhibitor Complex (PIC), tissue plasminogen activator-inhibitor complex (tPAIC), and thrombomodulin (TM).
- Logistic regression to assess the association between phenotypes and clinical endpoints.
Main Results:
- Two distinct DIC subtypes were identified: mild (n=79) and severe (n=55).
- Significant differences were observed in coagulation markers (TAT) and clinical parameters (HR, SBP) between subtypes.
- The severe subtype was associated with increased 7-day (OR 4.71) and 28-day (OR 2.29) mortality risk.
Conclusions:
- Unsupervised ML successfully stratified DIC patients into two distinct phenotypes.
- These phenotypes exhibit different laboratory profiles and associated mortality risks.
- The findings support personalized treatment strategies for DIC patients based on identified subtypes.
Related Concept Videos
Coagulation
1.6K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.6K
Coagulation
11.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
11.6K
Disorders of Hemostasis
2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
Clot Retraction and Fibrinolysis
9.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.9K

